<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02787148</url>
  </required_header>
  <id_info>
    <org_study_id>DFG EU 154 2 1</org_study_id>
    <nct_id>NCT02787148</nct_id>
  </id_info>
  <brief_title>Psychotherapy and Cardiovascular Risk Factors in Depression</brief_title>
  <official_title>The Impact of Psychotherapy on Hemodynamic and Inflammatory Risk Factors for Cardiovascular Disease in Major Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philipps University Marburg Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philipps University Marburg Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective studies indicate that patients with depression are at increased risk for&#xD;
      cardiovascular disease. Depression is also associated with a number of hemodynamic features,&#xD;
      which are known risk factors for cardiovascular morbidity such as increased heart rate,&#xD;
      reduced heart rate variability and blood pressure alterations. These hemodynamic alterations&#xD;
      may explain in part the increased cardiovascular risk associated with depression.&#xD;
&#xD;
      The purpose of this study is to determine whether treatment for depression with cognitive&#xD;
      behavior therapy (CBT) is effective in reducing hemodynamic cardiovascular risk factors.&#xD;
      Hemodynamic assessments including heart rate, heart rate variability, continues blood&#xD;
      pressure, blood pressure variability, baroreceptor sensitivity and peripheral vascular&#xD;
      resistance will be conducted at baseline, after treatment and 2-month follow up. In addition,&#xD;
      circadian hemodynamic variations such as 24-hour heart rate variability, nocturnal blood&#xD;
      pressure dipping and immunological biomarkers will be assessed. Eighty patients with Major&#xD;
      Depression will be randomly assigned to either a CBT treatment condition (14 hour-long,&#xD;
      weekly sessions) or a waitlist condition, to control for potential changes in hemodynamic&#xD;
      parameters without any intervention and the impact of repeated-measurement.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">October 2019</completion_date>
  <primary_completion_date type="Actual">October 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in depressive symptoms (BDI-II)</measure>
    <time_frame>Change from baseline (beginning of therapy) to 3 month after baseline, to 2-month-follow up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in heart rate variability</measure>
    <time_frame>Change from baseline (beginning of therapy) to 3 month after baseline, to 2-month-follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>Change from baseline (beginning of therapy) to 3 month after baseline, to 2-month-follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in baroreceptor sensitivity (ms/mmHg)</measure>
    <time_frame>Change from baseline (beginning of therapy) to 3 month after baseline, to 2-month-follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in peripheral vascular resistance (dyne*s/cm5)</measure>
    <time_frame>Change from baseline (beginning of therapy) to 3 month after baseline, to 2-month-follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C-reactive protein</measure>
    <time_frame>Change from baseline (beginning of therapy) to 3 month after baseline, to 2-month-follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in proinflammatory cytokines</measure>
    <time_frame>Change from baseline (beginning of therapy) to 3 month after baseline, to 2-month-follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anti-inflammatory interleukin-10</measure>
    <time_frame>Change from baseline (beginning of therapy) to 3 month after baseline, to 2-month-follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Subjective social status (MacArthur scale)</measure>
    <time_frame>Change from baseline (beginning of therapy) to 3 month after baseline, to 2-month-follow up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Cognitive behavioral therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cognitive behavioral therapy for Major Depression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Waitlist group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Waitlist group to control for repeated physiological measures and fluctuations over time</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive behavioral therapy</intervention_name>
    <arm_group_label>Cognitive behavioral therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with Major Depression (DSM IV), BDI &gt;=14&#xD;
&#xD;
          -  age:18-65 years&#xD;
&#xD;
          -  patients without antidepressive medication (stable for at least 2 weeks)&#xD;
&#xD;
          -  comorbidity with other psychiatric disorders is permitted, as far as depressive&#xD;
             symptoms are dominating&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  current psychotherapy&#xD;
&#xD;
          -  psychotic disorder&#xD;
&#xD;
          -  serious drug-addiction&#xD;
&#xD;
          -  drugs which seriously affect immune status (except contraceptives) or central&#xD;
&#xD;
          -  nervous system functions (except antidepressants)&#xD;
&#xD;
          -  infections during the last 2 weeks&#xD;
&#xD;
          -  injuries during the last 2 weeks&#xD;
&#xD;
          -  neurological disorders&#xD;
&#xD;
          -  diseases which affect immune status or central nervous system functions (e.g.&#xD;
             rheumatoid arthritis, CVD,etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Euteneuer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Psychology and Psychothearpy, Philipps University of Marburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Psychology and Psychotherapy, Philipps University Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>35032</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 10, 2016</study_first_submitted>
  <study_first_submitted_qc>May 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2016</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Philipps University Marburg Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. rer. nat. Frank Euteneuer</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>cognitive behavioral therapy</keyword>
  <keyword>psychotherapy</keyword>
  <keyword>cardiovascular health</keyword>
  <keyword>psychoneuroimmunology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

